Acromegaly is a chronic, slowly developing disease with progressive disfigurement and disability. An early diagnosis is difficult as most signs and symptoms are due to long-standing overproduction of growth hormone &/or insulin-like growth factor (IGF-I) causing metabolic, endocrine and morphological changes.
Surgical intervention is the first-line of treatment for almost all patients with acromegaly unless there are contraindications or the patient refuses to undergo the procedure.


Visual Field Testing 

  • Visual field assessment by perimetry is suggested to be done when tumor is abut the optic chiasm on an imaging study
  • It is also performed if the patient complains of reduced peripheral vision

Other Studies

  • Standard biochemistry (eg glucose, calcium, phosphorus, lipid profile, serum prolactin level)
  • Sleep studies for the evaluation of sleep apnea syndrome which is frequently associated with acromegaly
  • Periodic colonoscopy surveillance
    • Recommended to be done at diagnosis since incidence of pre-malignant colonic lesions may be higher in acromegaly

Laboratory Tests

Biochemical Tests

  • Insulin-like growth factor-I (IGF-1)
    • IGF-1 mesurements (adjusted for sex and age) are recommended initial screening as they are good tools to assess integrated growth hormone secretion and are excellent for screening, diagnosis, and monitoring
      • Recommended initial screening in patients with clinical manifestations of acromegaly especially those with facial and acral features
      • Also recommended in patients with associated conditions such as sleep apnea syndrome, type 2 diabetes mellitus, debilitating arthritis, carpal tunnel syndrome, hyperhidrosis and hypertension
    • May be used to rule out acromegaly in patients with pituitary mass
    • Long T1/2, integrated measure of growth hormone secretion over time because levels are growth hormone dependent
    • Diagnostic if >280 ng/mL with adjustments for age and gender
    • Normal IGF-1 effectively rules out the diagnosis of acromegaly
      • In pregnancy and late-stage adolescence, false positives may occur
    • Random insulin-like growth factor-I should be measured for diagnosis and for monitoring after a therapeutic intervention
  •  Growth Hormone
    • Random growth hormone measurement is not diagnostic due to its episodic secretion and short half-life (T½)
    • As growth hormone secretion is suppressed by glucose, measurement of growth hormone suppressibility with glucose is useful in the diagnosis of acromegaly 
    • Growth hormone measurements after 75-g oral glucose load
      • Nadir growth hormone suppression after administration of glucose is considered gold standard test for acromegaly
      • Inability to suppress growth hormone to <1.0 ng/mL is considered diagnostic for acromegaly; 0.4 ng/mL for growth hormone assays with increased sensitivity
        • Clinicians should investigate the assay being used to know the sensitivity
      • Recommended to be performed at baseline, then every 30 minutes for a total of 120 minutes after administration of glucose
    • Acromegaly is suggested if growth hormone level is not suppressed to:
      • <0.3 ng/mL with immunoradiometric (IRMA) or immunochemiluminescence assay
      • <0.1 ng/mL with conventional radioimmunoassay (RIA)


  • Performed after the above biochemical criteria for diagnosis are met
  • Magnetic resonance imaging (MRI) with gadolinium of the pituitary gland is the initial choice of imaging modality
    • Detection of tumor mass (eg pituitary adenoma)
    • Assess type, nature, size of tumor mass (eg macroadenoma or microadenoma)
  • CT scan is the next choice of imaging modality if MRI is contraindicated
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Editor's Recommendations
Most Read Articles
02 Jun 2017

Endocrine disruptors, which can be found in plastics, pesticides and receipts from thermal printers, have been linked to declining sperm quality in adults, says an expert.

Pank Jit Sin, 2 days ago
Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, recently received the National Pharmaceutical Regulatory Agency’s approval for an update on its indication.